Department of Defense Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Closed Solicitation Posted
- Solicitation number
- HT9402-24-Q-9302
- Agency
-
Defense Health Agency
Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Place of performance
- San Antonio, Texas 78230, United States
- Points of contact
Notice details come from SAM.gov. Updated .
About this opportunity
The Department of Defense (DoD) Defense Health Agency (DHA) is issuing a Request for Quotation (RFQ) to obtain pharmaceutical agents for the DoD Pharmacy Uniform Formulary Blanket Purchase Agreement (UF BPA) and Uniform Formulary Additional Discount Program (UF ADP). The RFQ seeks quotes from industry for agents within the Gastrointestinal-2 Agents, Tumor Necrosis Factor Inhibitors, and Targeted Immunomodulatory Biologics drug classes to be considered for placement on the DoD Uniform Formulary at the August 2024 Pharmacy and Therapeutics (P&T) Committee meeting. Quotes are due by May 9, 2024, and the DHA may award UF BPA and UF ADP agreements based on the P&T Committee's formulary decisions. Interested companies must also respond to clinical questions by the same date, and a pre-quotation teleconference is scheduled for April 24, 2024.
This procurement is not set-aside, and the NAICS code is likely 325412 (Pharmaceutical Preparation Manufacturing). The solicitation number is HT9402-24-Q-9302, and the place of performance is San Antonio, TX. The DoD is seeking discounts and pricing information from pharmaceutical manufacturers for potential placement of their products on the DoD Uniform Formulary, which could result in increased utilization and sales within the Military Health System.
Notice text
The Department of Defense (DoD) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoD Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoD Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ.
P&T COMMITTEE MEETING: August 2024: The following drug classes/subclass will be reviewed:
a. Rezdiffra - Gastrointestinal-2 AGENTS - Subclass: NA
b. Humira by Cordavis - Targeted Immunomodulatory Biologics - Subclass: Tumor Necrosis Factor Inhibitors
c. Simlandi - Targeted Immunomodulatory Biologics - Subclass: Tumor Necrosis Factor Inhibitors
The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-24-Q-9302.
Pre-quotation teleconference is on April 24, 2024, details are stated in Part 2.5. Pre-quotation teleconference, contact RFQ Point of Contact (POC) for agenda and dial-in information. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC (stated in Part 2.3), no later than the date stated in Part 2.4.
Files
| File | Type | Posted |
|---|---|---|
| NAD RFQ1 - Humira by Cordavis - TIB - TNFI.xlsx | XLSX spreadsheet | |
| RFQ HT9402-24-Q-9302 NAD.pdf | ||
| NAD RFQ1 - Simlandi - TIB - TNFI.xlsx | XLSX spreadsheet | |
| NAD RFQ1 - Rezdiffra - GAST-2 AGENTS - NA.xlsx | XLSX spreadsheet | |
| DoD Formulary Placement of FDA Newly Approved Drugs.pdf | ||
| Price Appendix FAQ NAD.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity